{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.2","upperLimit":"55.0","value":"48.8"},{"groupId":"OG001","lowerLimit":"29.9","upperLimit":"42.2","value":"36.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"264"},{"groupId":"OG001","value":"266"}],"units":"Participants"}],"description":"PFS per RECIST 1.1 assessed by BICR was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from therapy or received another anticancer therapy prior to progression. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir) - this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm from nadir. The PFS18 was defined as the Kaplan-Meier estimate of PFS per RECIST 1.1 as assessed by BICR at 18 months following randomization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received durvalumab monotherapy (1500 mg for participants \\>30 kg in weight and a weight-based dosing equivalent to 20 mg/kg for participants \\<=30 kg in weight) via IV infusion once q4w, until clinical/RECIST 1.1-defined radiological progression, intolerable toxicity, or for a maximum of 24 months, whichever occurred first.","id":"OG000","title":"Durvalumab"},{"description":"Participants received matching placebo via IV infusion once q4w for 4 doses/cycles each, until clinical/RECIST 1.1-defined radiological progression, intolerable toxicity, or for a maximum of 24 months, whichever occurred first.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Month 18","title":"Durvalumab Versus Placebo: Percentage of Participants Progression-Free at 18 Months Following Randomization (PFS18) Assessed by Blinded Independent Central Review Per Response Evaluation Criteria in Solid Tumors Version 1.1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}